ArticlePractical radiation oncology
Reirradiation With Three-Fraction Stereotactic Body Radiation Therapy for Spinal Metastases.
Article in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeWe sought to characterize outcomes from a large institutional database of patients treated with 3-fraction spine stereotactic body radiation therapy (SBRT) after prior overlapping radiation therapy. METHODS AND MATERIALS: The primary outcome of interest was local failure (LF) in the treated lesion, defined based on magnetic resonance imaging. We also characterized toxicities such as vertebral compression fracture and radiation myelitis.
resultsThere were 83 patients treated to 87 spinal lesions between 2014 and 2023. Median follow-up was 14.2 (IQR, 6-29.4) months, and median overall survival was 20.5 (95% CI, 16.5-29.9) months. Most lesions were treated with 27 Gy in 3 fractions (n = 78; 90%). Most lesions had been treated with prior conventionally fractionated radiation therapy (59%), and the most common histology was prostate cancer (n = 15; 17%). The 1- and 2-year LF rate was 8.4% (95% CI, 3.7%-16%) and 15% (95% CI, 8.1%-24%), respectively. On univariable analysis, lower minimum dose to the planning target volume (hazard ratio, 0.85, 95% CI, 0.74-0.99, P = .03) and colorectal, cholangio-, or hepatocellular carcinoma histology (hazard ratio 5.6, 95% CI, 1.11-28.4, P = .037) were associated with risk of LF. There was 1 case of radiation myelitis (1.3%) and 5 cases (5.5%) of vertebral compression fracture.
conclusionReirradiation with spine SBRT in 3 fractions appears safe and is associated with a 2-year local control rate of 85%. Lower planning target volume, lower minimum dose, and gastrointestinal histology were associated with increased risk of LF. Further work is needed to identify the optimal dose-fractionation regimen for reirradiation with spine SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.